Diego Díaz García, Medical Oncologist, CEO and Founder of CánCare, posted on X:
“Cancer of Unknown Primary (CUP) remains a clinical challenge.
Diagnosis relies on immunophenotyping + molecular profiling. Site-specific therapy or platinum-based chemo are standard. Prognosis is poor, trial enrollment is key.”
Title: Cancer of Unknown Primary Site
Authors: Kanwal Raghav
Read the Full Article.
